<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04573452</url>
  </required_header>
  <id_info>
    <org_study_id>G-PA</org_study_id>
    <nct_id>NCT04573452</nct_id>
  </id_info>
  <brief_title>Galectin-3 and Placenta Accreta</brief_title>
  <official_title>The Role of Galectin-3 in the Pathogenesis and Prediction of Placenta Accreta</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Galectins are a family of carbohydrate-binding proteins that have a high affinity to&#xD;
      galactosides, its protein portion is located in the nucleus and the cytoplasm with its&#xD;
      carbohydrate recognition domain which has high ability to be glycosylated inside or outside&#xD;
      the cell.&#xD;
&#xD;
      They are expressed by vascular endothelium, immune cells (macrophages, neutrophils, and mast&#xD;
      cells), uterus, placenta, cardiac muscle, liver, epithelium of the gastrointestinal tract,&#xD;
      and many other tissues.&#xD;
&#xD;
      Although some galectins have intracellular functions, the majority of them have extracellular&#xD;
      activities, which facilitate their contribution to cell adhesion, cell activation, and&#xD;
      inflammation. Galectin-3 (Gal-3) is a unique pentamer of the galectins family and it is&#xD;
      involved in both physiological functions; cell growth and differentiation, and pathological&#xD;
      conditions; inflammation, fibrosis, and metastasis.&#xD;
&#xD;
      Regarding pregnancy, Gal-3 is proved to participate in angiogenesis, embryo developmental&#xD;
      processes, and modulation of maternal immunity.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Crossover</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Galactin 3 level in the blood</measure>
    <time_frame>6 weeks</time_frame>
    <description>measured by ng/ml</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Placenta Accreta</condition>
  <arm_group>
    <arm_group_label>Normal pregnancy group</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Placenta accreta at 32 weeks group</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Placenta accreta at 37 weeks group</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Galectin-3</intervention_name>
    <description>Measurement of Gal-3 in Serum which will be isolated from the blood samples by ELISA (Enzyme-Linked immunosorbent Assay) (R&amp;D Systems, Minneapolis, MN, USA).</description>
    <arm_group_label>Normal pregnancy group</arm_group_label>
    <arm_group_label>Placenta accreta at 32 weeks group</arm_group_label>
    <arm_group_label>Placenta accreta at 37 weeks group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Placental Galactin-3</intervention_name>
    <description>Measurement of Gal-3 in Villous and decidual tissues homogenate by ELISA</description>
    <arm_group_label>Normal pregnancy group</arm_group_label>
    <arm_group_label>Placenta accreta at 37 weeks group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Pregnant women&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Pregnant women between 28-32 weeks.&#xD;
&#xD;
          2. Age between 20-40 years.&#xD;
&#xD;
          3. Singleton pregnancy.&#xD;
&#xD;
          4. Women with suspicion of placenta accreta&#xD;
&#xD;
          5. Cases with mild vaginal bleeding or not having any vaginal bleeding.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Women are known to have any medical disorders.&#xD;
&#xD;
          2. Patients with known bleeding disorders or on anticoagulant therapy.&#xD;
&#xD;
          3. Patients refuse to participate.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Women Health Hospital - Assiut university</name>
      <address>
        <city>Assiut</city>
        <zip>71111</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohammed K ALi, MD</last_name>
      <phone>+201005537951</phone>
      <email>m_khairy2001@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 28, 2020</study_first_submitted>
  <study_first_submitted_qc>September 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2020</study_first_posted>
  <last_update_submitted>September 28, 2020</last_update_submitted>
  <last_update_submitted_qc>September 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Mohammed Khairy Ali</investigator_full_name>
    <investigator_title>Assistant professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Placenta Accreta</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

